NLRP3炎性小体在心脏病发病中的作用研究进展

doi:10.16352/j.issn.1001-6325.2023.07.1162

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (7): 1162-1166.doi: 10.16352/j.issn.1001-6325.2023.07.1162

NLRP3炎性小体在心脏病发病中的作用研究进展

高源¹, 郑刚^1,*, 齐靖², 张凤¹

1.陕西中医药大学, 陕西咸阳 712000;
2.陕西中医药大学第二附属医院科研科,陕西咸阳 712046

收稿日期:2021-11-01 修回日期:2022-05-06 发布日期:2023-07-05
通讯作者: ^* zhenggang2283@163.com

Progress of NLRP3 inflammasome in the pathogenesis of heart disease

GAO Yuan¹, ZHENG Gang^1,*, QI Jing², ZHANG Feng¹

1. Shaanxi University of Traditional Chinese Medicine, Xianyang 712000;
2. Department of Scientific Research, the Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang 712046, China

Received:2021-11-01 Revised:2022-05-06 Published:2023-07-05

摘要/Abstract

摘要： NLRP3炎性小体是最具特征的炎性体,其可参与心力衰竭、心肌梗死、动脉粥样硬化以及心律失常等心脏病的发病过程,抑制NLRP3炎性小体激活可有效治疗心脏病。炎性小体的组装和激活过程较为复杂,揭示其活化过程及其与心脏病的关系有望开发出新型靶向防治心脏疾病的药物。

关键词: NLRP3炎性小体, 心血管疾病, 炎性反应

Abstract: NLRP3 inflammatsome is the most characteristic inflammasome. It can play some roles in the pathogenesis of heart diseases such as heart failure, myocardial infarction, atherosclerosis and arrhythmia. Inhibiting the activation of NLRP3 inflammasome can effectively treat heart diseases. The assembly and activation process of inflammasome are complex. Revealing its activation process and its relationship with heart disease may develop new drugs targeting at the prevention and treatment of heart disease.

Key words: NLRP3 inflammasome, cardiovascular disease, inflammatory reaction

中图分类号:

R392.12

高源, 郑刚, 齐靖, 张凤. NLRP3炎性小体在心脏病发病中的作用研究进展[J]. 基础医学与临床, 2023, 43(7): 1162-1166.

GAO Yuan, ZHENG Gang, QI Jing, ZHANG Feng. Progress of NLRP3 inflammasome in the pathogenesis of heart disease[J]. Basic & Clinical Medicine, 2023, 43(7): 1162-1166.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.07.1162

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I7/1162

参考文献

[1] Schunk S,Kleber M,März W, et al. Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality[J].Eur Heart J, 2021, 42: 1742-1756.
[2] Hoseini Z,Sepahvand F,Rashidi B, et al. NLRP3 inflammasome: its regulation and involvement in atherosclerosis[J].J Cell Physiol, 2018, 233: 2116-2132.
[3] Pellegrini C,Martelli A,Antonioli L, et al. NLRP3 inflammasome in cardiovascular diseases: pathophysiological and pharmacological implications[J].Med Res Rev, 2021, 41: 1890-1926.
[4] Corcoran S,Halai R,Cooper M, et al. Pharmacological inhibition of the nod-like receptor family pyrin domain containing 3 inflammasome with MCC950[J].Pharmacol Rev, 2021, 73: 968-1000.
[5] Wang ZH,Wei K,Lu C, et al. Targeting NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome in cardiovascular disorders[J].Arterioscler Thromb Vasc Biol, 2018, 38: 2765-2779.
[6] Christgen S,Place D,Kanneganti T.Toward targeting inflammasomes: insights into their regulation and activation[J].Cell Res, 2020, 30: 315-327.
[7] Liu DL,Zeng X,Li X, et al. Role of NLRP3 inflamma-some in the pathogenesis of cardiovascular diseases[J].Basic Res Cardiol, 2018, 113: 265-273.
[8] Chong WC,Shastri M,Peterson G, et al. The complex interplay between endoplasmic reticulum stress and the NLRP3 inflammasome: a potential therapeutic target for inflammatory disorders[J].Clin Transl Immunol, 2021, 10: 381-389.
[9] Shen J,Ma H,Wang C.Triptolide improves myocardial fibrosis in rats through inhibition of nuclear factor kappa B and NLR family pyrin domain containing 3 inflammasome pathway[J].Korean J Physiol Pharmacol, 2021, 25: 533-543.
[10] Abbate A,Toldo S,Marchetti C, et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease[J].Circ Res, 2020, 126: 1260-1280.
[11] Lim G.Heart failure: clonal haematopoiesis, IL-1β, and the NLRP3 inflammasome in HF[J].Nat Rev Cardiol, 2018, 15: 198-212.
[12] Sano S,Oshima K,Wang Y, et al. Tet2-Mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome[J].J Am Coll Cardiol, 2018, 71: 875-886.
[13] Ridker P,Rane M.Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease[J].Circ Res, 2021, 128: 1728-1746.
[14] Grebe A,Hoss F,Latz E.NLRP3 inflammasome and the IL-1 pathway in atherosclerosis[J].Circ Res, 2018, 122: 1722-1740.
[15] Fuster J.Integrated stress response inhibition in atherosclerosis: preventing the stressed-out plaque[J].J Am Coll Cardiol, 2019, 73: 1170-1172.
[16] Chen X,Guo X,Ge Q, et al. ER stress activates the NLRP3 inflammasome: a novel mechanism of atherosclerosis[J].Oxid Med Cell Longev, 2019, 2019: 346-362.
[17] Abbate A,Toldo S,Marchetti C, et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease[J].Circ Res, 2020, 126: 1260-1280.
[18] Sreejit G,Abdel LA,Athmanathan B, et al. Neutrophil-derived S100A8/A9 amplify granulopoiesis after myo-cardial infarction[J].Circulation, 2020, 141: 1080-1094.
[19] Everett B,Mac FG,Thuren T, et al. Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS trial[J].J Am Coll Cardiol, 2020, 76: 1660-1670.
[20] Lv SL,Zeng ZF,Gan WQ, et al. Lp-PLA2 inhibition prevents Ang Ⅱ-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation[J].Acta Pharmacol Sin, 2021, 42: 2016-2032.
[21] Yan Z,Qi Z,Yang X, et al. The NLRP3 inflammasome: multiple activation pathways and its role in primary cells during ventricular remodeling[J].J Cell Physiol, 2021, 236: 5547-5563.
[22] Scott L,Fender A,Saljic A, et al. NLRP3 inflammasome is a key driver of obesity-induced atrial arrhythmias[J].Cardiovasc Res, 2021, 117: 1746-1759.
[23] Wei Z,Fei Y,Wang Q, et al. Loss of Camk2n1 aggravates cardiac remodeling and malignant ventricular arrhythmia after myocardial infarction in mice via NLRP3 inflammasome activation[J].Free Radic Biol Med, 2021, 167: 243-257.

NLRP3炎性小体在心脏病发病中的作用研究进展

Progress of NLRP3 inflammasome in the pathogenesis of heart disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任鹏, 陈雅丽, 张娴文. 帕金森病嗅觉障碍的研究进展[J]. 基础医学与临床, 2023, 43(6): 994-997.
[2]	季玮, 朱玥, 尧惠慈, 卢红艳. 白三烯C4及2型固有淋巴细胞在支气管肺发育不良中的变化及意义[J]. 基础医学与临床, 2023, 43(5): 711-716.
[3]	雷星煜, 冯雪松, 晁旭. 11β-HSD1在炎性反应、肝癌的发生发展与免疫中作用的研究进展[J]. 基础医学与临床, 2023, 43(5): 837-841.
[4]	孙莹, 杨治安, 何瑶, 余勤. HMGB1信号通路在支气管哮喘中作用的研究进展[J]. 基础医学与临床, 2023, 43(4): 690-694.
[5]	录亚鹏, 谢建琴. NLRP3炎性小体在缺血再灌注损伤治疗中作用的研究进展[J]. 基础医学与临床, 2023, 43(4): 706-710.
[6]	李立亚, 秦霈. 星形胶质细胞在中枢神经系统炎性疾病中作用的研究进展[J]. 基础医学与临床, 2023, 43(4): 665-668.
[7]	蒋烨, 余卓颖, 李民. 炎性反应在糖尿病神经病变发生中作用的研究进展[J]. 基础医学与临床, 2023, 43(4): 669-673.
[8]	杜丰禾, 刘暴. 血管周围脂肪组织炎性反应促进动脉粥样硬化作用机制的研究进展[J]. 基础医学与临床, 2023, 43(4): 685-689.
[9]	刘芬, 胡润芳, 茅松, 徐敏, 石文静, 陈凌. 地塞米松减轻过敏性哮喘模型小鼠气道炎性反应[J]. 基础医学与临床, 2023, 43(3): 402-407.
[10]	秦玉春, 邝向东, 蔡林再, 谢景臣, 陈山. 双氢青蒿素减轻慢性阻塞性肺疾病(COPD)模型大鼠肺损伤[J]. 基础医学与临床, 2023, 43(3): 427-432.
[11]	代志新, 王玉敏. NLRP3炎性小体在高尿酸血症肾病中作用的研究进展[J]. 基础医学与临床, 2023, 43(2): 322-326.
[12]	付士祥, 席月, 丁龙坤, 闫曼, 赵俊, 焦玉东, 吴亮. 鲍曼不动杆菌外膜囊泡诱发人单核-巨噬细胞THP-1的炎性反应[J]. 基础医学与临床, 2023, 43(1): 110-115.
[13]	曾颖, 付桂莉. 黄芩提取物抑制IL-22诱导的人角质形成细胞系HaCaT过度增殖[J]. 基础医学与临床, 2023, 43(1): 123-129.
[14]	杨广林, 任丽娟, 陈文静, 熊维军. LncRNA MINCR靶向miR-223抑制LPS诱导的人肺泡上皮细胞系A549损伤和炎性反应[J]. 基础医学与临床, 2023, 43(1): 102-109.
[15]	顾炜, 祝剑平, 吴品雯. 丙泊酚减轻低氧诱导的大鼠肾上腺嗜铬细胞瘤细胞系PC12炎性反应和细胞凋亡[J]. 基础医学与临床, 2023, 43(1): 137-143.